Cizzle Biotechnology to Raise £0.62m for Scale Up of Key Antibodies and Reagents (VIDEO)

Cizzle Biotechnology Holdings PLC (LON:CIZ), the UK based diagnostics developer, has announced that it has undertaken a conditional placing of 31,050,000 new ordinary shares of 0.01p each in the Company at a price of 2 pence per share raising approximately £0.62 million before expenses for the Company.

Allenby Capital Limited is acting as sole broker in connection with the Placing. The Placing has been conducted with existing and new investors.

DirectorsTalk caught up with Cizzle Biotechnology Executive Chairman, Dr Allan Syms to discuss the news

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Cizzle Biotech

    More articles like this

    Cizzle Biotech

    Cizzle Biotechnology completes evaluation programme with Bio-Techne

    Bio-Techne Corporation (NASDAQ: TECH) and Cizzle Biotechnology Holdings plc (LON:CIZ), the UK-based diagnostics developer, have announced recent progress evaluating specific monoclonal antibodies for Cizzle’s CIZ1B cancer biomarker. Cizzle has successfully completed an evaluation programme aimed at assessing the feasibility of

    Cizzle Biotech

    Cizzle Biotechnology secures transaction with Conduit

    Cizzle Biotechnology Holdings plc (LON:CIZ), the UK based diagnostics developer, has announced that it has agreed a put option to sell: (i) its 5% economic interest in the commercialisation of the AZD 1656 asset to treat